Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Invested Capital (2016 - 2025)

Historic Invested Capital for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $24.2 million.

  • Sunshine Biopharma's Invested Capital fell 335.45% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 335.45%. This contributed to the annual value of $23.5 million for FY2024, which is 1081.41% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Invested Capital is $24.2 million, which was down 335.45% from $25.7 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Invested Capital registered a high of $41.9 million during Q2 2022, and its lowest value of -$1.2 million during Q3 2021.
  • Over the past 5 years, Sunshine Biopharma's median Invested Capital value was $22.7 million (recorded in 2025), while the average stood at $19.6 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Invested Capital soared by 1011797.49% in 2022, and later crashed by 4561.36% in 2023.
  • Sunshine Biopharma's Invested Capital (Quarter) stood at $211662.0 in 2021, then skyrocketed by 10117.97% to $21.6 million in 2022, then decreased by 1.94% to $21.2 million in 2023, then rose by 10.81% to $23.5 million in 2024, then rose by 2.97% to $24.2 million in 2025.
  • Its last three reported values are $24.2 million in Q3 2025, $25.7 million for Q2 2025, and $22.7 million during Q1 2025.